News from novo nordisk A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 24, 2020, 01:23 ET El cambio a la insulina icodec de administración semanal y en etapa de investigación desde otras insulinas basales demostró ser eficaz y bien tolerado para pacientes con diabetes tipo 2 en un ensayo clínico de fase 2

Novo Nordisk anunció hoy los resultados de tres ensayos clínicos de fase 2 de la insulina icodec, un análogo de insulina basal de administración...


Sep 24, 2020, 01:23 ET A mudança de outras insulinas basais para a insulina sob investigação icodec uma vez por semana demonstrou ser eficaz e bem tolerada por pessoas com diabetes tipo 2 em um estudo clínico de fase 2

Hoje, a Novo Nordisk anunciou os resultados de três estudos clínicos de fase 2 com a insulina icodec, um análogo sob investigação da insulina basal...


Jun 14, 2020, 19:30 ET Investigational, once-weekly insulin icodec showed comparable efficacy and safety to once-daily insulin glargine U100 in phase 2 trial

Today, Novo Nordisk announced results from a phase 2 clinical trial of investigational insulin icodec, a once-weekly basal insulin analog. In the...


Jun 02, 2020, 09:04 ET Novo Nordisk to present new data at the 80th Annual American Diabetes Association Scientific Sessions

Novo Nordisk announced that new data from 38 abstracts will be featured from the company's approved and investigational diabetes medicines at the...


Mar 31, 2020, 13:44 ET New England Journal of Medicine publishes phase 3 trial data demonstrating improvements in BMI and body weight in adolescents with obesity taking Saxenda®

Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of...


Jan 16, 2020, 17:56 ET FDA approves Ozempic® for cardiovascular risk reduction in adults with type 2 diabetes and known heart disease, updates Rybelsus® label

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Ozempic® (semaglutide) injection 0.5...


Jan 06, 2020, 09:05 ET FDA approves Fiasp® for treatment of children with diabetes

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Fiasp® (insulin aspart injection) 100 u/mL for use as a...


Nov 19, 2019, 08:50 ET New "Cities Changing Diabetes" public-private partnership in Philadelphia mobilizing against city's diabetes epidemic

More than 100 health, faith, business and community leaders from across Philadelphia gathered today to learn about emerging research that identify...


Nov 12, 2019, 08:00 ET New Online Reality Series with Actor, Comedian Billy Gardell Chronicles Type 2 Diabetes Transformation Journey

Billy Gardell, star of CBS's hit, new sitcom Bob Hearts Abishola, has teamed up with Novo Nordisk, a company focused on helping people with diabetes, ...


Oct 22, 2019, 09:10 ET FDA approves Fiasp® for use in insulin infusion pumps for adults with type 1 or type 2 diabetes

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has expanded the label for Fiasp® (insulin aspart injection) 100 u/mL...


Sep 20, 2019, 10:49 ET FDA approves Rybelsus® (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Rybelsus® (semaglutide) tablets 7 mg or 14 mg for adults...


Sep 10, 2019, 10:03 ET New global survey highlights impact of diabetes management on family members

According to a new international survey of 4,300 family members of people living with type 1 and type 2 diabetes, many report worrying about their...


Aug 14, 2019, 13:00 ET Calling life science innovators: don't miss your chance for a "Golden Ticket" to LabCentral

Wanted: high-potential life sciences and biotech start-up companies looking for an opportunity to be part of a vibrant innovation ecosystem where...


Jun 17, 2019, 17:41 ET FDA approves Victoza® for the treatment of type 2 diabetes in children and adolescents aged 10-17 years

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Victoza® (liraglutide)...


Jun 11, 2019, 14:45 ET Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular...


Jun 08, 2019, 11:45 ET Oral semaglutide showed superior reductions in blood sugar vs Jardiance® and non-inferior blood sugar reductions vs Victoza® in adults with type 2 diabetes at 26 weeks

Findings presented today from two phase 3a clinical trials evaluated oral semaglutide 14 mg vs Jardiance® (empagliflozin 25 mg) in PIONEER 2 and oral ...


May 22, 2019, 10:43 ET Novo Nordisk to present data on oral semaglutide at the 79th Annual American Diabetes Association Scientific Sessions

Novo Nordisk today announced that new data from its diabetes portfolio will be presented at the upcoming 79th Annual Scientific Sessions of the...


Apr 30, 2019, 12:15 ET Renewable electricity to completely power Novo Nordisk US operations in early 2020

Beginning in early 2020, Novo Nordisk's global production will be completely powered by renewable electricity, with a ten-year goal of achieving zero ...


Apr 28, 2019, 18:00 ET Victoza® demonstrated superiority in reducing blood sugar vs placebo in children and adolescents with type 2 diabetes

Novo Nordisk today announced the results from the ELLIPSE trial which examined efficacy and safety and demonstrated superiority of Victoza®...


Mar 23, 2019, 14:00 ET Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO

Oral semaglutide 7 mg and 14 mg demonstrated superior A1C and body weight reductions compared to Januvia® (sitagliptin 100 mg). Non-inferiority for...


Mar 20, 2019, 10:08 ET Novo Nordisk files for US FDA approval of oral semaglutide for blood sugar control and cardiovascular risk reduction in adults with type 2 diabetes

Novo Nordisk today announced the submission of two New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for oral semaglutide,...


Mar 04, 2019, 08:03 ET Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors

Novo Nordisk today announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology. The objective of this...


Mar 01, 2019, 07:00 ET Novo Nordisk files for a label update for Fiasp® to the EMA and the FDA seeking approval for use in children and adolescents

Novo Nordisk today announced that it recently submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration...


Oct 22, 2018, 12:46 ET Cardiovascular safety data added to Saxenda® label

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved an updated label for Saxenda® (liraglutide) injection 3 mg....


Jun 23, 2018, 10:12 ET Tresiba® demonstrated significantly lower A1C and rates of hypoglycaemia versus insulin glargine U-300 in real-world evidence study

Findings from CONFIRM – a large, retrospective real-world evidence (RWE) study comparing the effectiveness of Tresiba® (insulin degludec injection)...